IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4225
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$16M
Joshua N. Silverman
PharmaCyte Biotech, Inc. focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$PMCB PharmaCyte Biotech, Inc. | 34 | 38 | 26 | 18 | - | - | -66.2% | -41.7% | - | - | - | - | 0.0% | 55.0x | $16M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
PharmaCyte Biotech, Inc. (PMCB) receives a "Avoid" rating with a composite score of 33.8/100. It ranks #4225 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for PMCB.
View All RatingsROE proxy -66.2% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 11yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate PharmaCyte Biotech, Inc. (PMCB) as Avoid with a composite score of 33.8/100 at a current price of $0.73. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
PharmaCyte Biotech, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 33.8/100 places it at rank #4225 in our full universe.
No Moat
Medium
Poor
Fair Value
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
PharmaCyte Biotech, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags PharmaCyte Biotech, Inc. with an Avoid rating, assigning a composite score of 33.8/100 and 1 out of 5 stars. Ranked #4225 of 7,333 stocks, PMCB falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
PMCB's quality score of 38/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -66.2% (sector avg: -1.9%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
PMCB registers a value score of just 26/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.20x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
PharmaCyte Biotech, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -41.7% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
PharmaCyte Biotech, Inc. is experiencing notably weak momentum with a score of just 18/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 0.64 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
PMCB's stability score of 44/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.64 and a debt-to-equity ratio of 55.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
PMCB carries a short interest score of 68/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 55.00x), micro-cap liquidity risk. At $16M market cap (micro-cap), PharmaCyte Biotech, Inc. offers reasonable institutional liquidity.
PharmaCyte Biotech, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4225 of 7,333 overall (42nd percentile). Key comparisons include ROE of -66.2% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While PMCB currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (18) would have the largest impact on the composite score.
ROE 3386% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 26090% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (NASDAQ: ADGI) (IPOed Aug. 6) Alkermes plc (NASDAQ: ALKS) Bio-Rad Laboratories, Inc. (NYSE: BIO) Candel Therapeutics, Inc. (NASDAQ: CADL) (IPOed July 26) Century Therapeutics, Inc. (NASDAQ: IPSC) (reacted to its second-quarter results) Dynavax Technologies Corporation (NASDAQ: DVAX) Gilead Sciences, Inc. (NASDAQ: GILD) Harvard Bioscience, Inc. (NASDAQ: HBIO) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Innoviva, Inc. (NASDAQ: INVA) Johnson & Johnson (NYSE: JNJ) Sesen Bio, Inc. (NASDAQ: SESN) Tenaya Therapeutics, Inc. (NASDAQ: TNYA) (IPOed July 30) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 12) ABVC BioPharma, Inc. (NASDAQ: ABVC) (announced its second-quarter results) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Achilles Therapeutics plc (NASDAQ: ACHL) Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) Akero Therapeutics, Inc. (NASDAQ: AKRO) Allogene Therapeutics, Inc. (NASDAQ: ALLO) Alzamend Neuro, Inc. (NASDAQ: ALZN) Aprea Therapeutics, Inc. (NASDAQ: APRE) (announced that FDA imposed clinical hold on lymphoid malignancy study) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) (announced second-quarter results) Atai Life Sciences N.V. (NASDAQ: ATAI) (announced setting up of a subsidiary for studying Salvinorin A for mental health disorders) Axsome Therapeutics, Inc. (NASDAQ: AXSM) Aytu Biopharma, Inc. (NASDAQ: AYTU) Baudax Bio, Inc. (NASDAQ: BXRX) Baxter International Inc. (NYSE: BAX) Biodesix, Inc. (NASDAQ: BDSX) Biomea Fusion, Inc. (NASDAQ: BMEA) Cellectar Biosciences, Inc. (NASDAQ: CLRB) Celularity Inc. (NASDAQ: CELU) Codex DNA, Inc. (NASDAQ: DNAY) CytomX Therapeutics, Inc. (NASDAQ: CTMX) DiaMedica Therapeutics Inc. (NASDAQ: DMAC) (reacted to its second-quarter results) Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) Edgewise Therapeutics, Inc. (NASDAQ: EWTX) Ensysce Biosciences, Inc. (NASDAQ: ENSC) Epizyme, Inc. (NASDAQ: EPZM) Exicure, Inc. (NASDAQ: XCUR) (announced its second-quarter results) EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) FibroGen, Inc. (NASDAQ: FGEN) Flexion Therapeutics, Inc. (NASDAQ: FLXN) Grifols, S.A. (NASDAQ: GRFS) Heron Therapeutics, Inc. (NASDAQ: HRTX) HOOKIPA Pharma Inc. (NASDAQ: HOOK) (reacted to its second-quarter result) Hoth Therapeutics, Inc. (NASDAQ: HOTH) IMARA Inc. (NASDAQ: IMRA) IN8bio, Inc. (NASDAQ: INAB) Incyte Corporation (NASDAQ: INCY) Inhibikase Therapeutics, Inc. (NASDAQ: IKT) iRhythm Technologies, Inc. (NASDAQ: IRTC) Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) Kronos Bio, Inc. (NASDAQ: KRON) Lava Therapeutics B.V. (NASDAQ: LVTX) Liminal BioSciences Inc. (NASDAQ: LMNL) Lumos Pharma, Inc. (NASDAQ: LUMO) MediciNova, Inc. (NASDAQ: MNOV) Moleculin Biotech, Inc. (NASDAQ: MBRX) (reacted to its second-quarter ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (NASDAQ: ADGI) (IPOed Friday) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Cytek Biosciences, Inc. (NASDAQ: CTKB) Dynavax Technologies Corporation (NASDAQ: DVAX) Eliem Therapeutics, Inc. (NASDAQ: ELYM) (IPOed Monday) Erasca, Inc. (NASDAQ: ERAS) (IPOed July 16) Fulcrum Therapeutics, Inc. (NASDAQ: FULC) (reacted to positive analyst actions following a positive clinical readout) IN8bio, Inc. (NASDAQ: INAB) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) (announced second-quarter results) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) (IPOed July 30) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 11) Adicet Bio, Inc. (NASDAQ: ACET) Akero Therapeutics, Inc. (NASDAQ: AKRO) Allogene Therapeutics, Inc. (NASDAQ: ALLO) Aptose Biosciences Inc. (NASDAQ: APTO) Ardelyx, Inc. (NASDAQ: ARDX) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) AVROBIO, Inc. (NASDAQ: AVRO) Baudax Bio, Inc. (NASDAQ: BXRX) Biodesix, Inc. (NASDAQ: BDSX) (reacted to second-quarter results) Cellectar Biosciences, Inc. (NASDAQ: CLRB) Celularity Inc. (NASDAQ: CELU) Codex DNA, Inc. (NASDAQ: DNAY) (announced second-quarter results) CytomX Therapeutics, Inc. (NASDAQ: CTMX) Edgewise Therapeutics, Inc. (NASDAQ: EWTX) Ensysce Biosciences, Inc. (NASDAQ: ENSC) Epizyme, Inc. (NASDAQ: EPZM) Eton Pharmaceuticals, Inc. (NASDAQ: ETON) Exicure, Inc. (NASDAQ: XCUR) EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) FibroGen, Inc. (NASDAQ: FGEN) (received a complete response letter for its anemia drug regulatory application) Freeline Therapeutics Holdings plc (NASDAQ: FRLN) Grifols, S.A. (NASDAQ: GRFS) Harpoon Therapeutics, Inc. (NASDAQ: HARP) Ikena Oncology, Inc. (NASDAQ: IKNA) IMARA Inc. (NASDAQ: IMRA) Incyte Corporation (NASDAQ: INCY) Inventiva S.A. (NASDAQ: IVA) iRhythm Technologies, Inc. (NASDAQ: IRTC) Kamada Ltd. (NASDAQ: KMDA) (announced second-quarter results) Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) Kronos Bio, Inc. (NASDAQ: KRON) Kura Oncology, Inc. (NASDAQ: KURA) Lumos Pharma, Inc. (NASDAQ: LUMO) Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) MediciNova, Inc. (NASDAQ: MNOV) Nautilus Biotechnology, Inc. (NASDAQ: NAUT) Nektar Therapeutics (NASDAQ: NKTR) Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Nevro Corp. (NYSE: NVRO) Nuvation Bio Inc. (NYSE: NUVB) OptiNose, Inc. (NASDAQ: OPTN) Otonomy, Inc. (NASDAQ: OTIC) Outset Medical, Inc. (NASDAQ: OM) PharmaCyte Biotech, Inc. Common Stock (NASDAQ: PMCB) Relmada Therapeutics, Inc. (NASDAQ: RLMD) (announced second-quarter results) Rockwell ...
Meta Platforms, Inc. announced a whopping $40 billion share repurchase program.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.